Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mati Therapeutics
Austin, Texas, United Statesmatitherapeutics.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Mati Therapeutics has developed the Evolute® Punctal Plug Delivery System—a minimally invasive device placed in the tear duct to deliver sustained-release medication directly to the eye. The lead program uses this technology to deliver latanoprost for glaucoma and ocular hypertension. The company’s leadership team has deep ophthalmology experience from major industry players. Clinical development appears advanced with at least one program at Phase III/commercial scale-up.
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug-device combination (sustained-release drug delivery via punctal plug)Small molecules (e.g., latanoprost)
- Industry
- Implantable Medical Devices
Beyond the preview
Go deeper on Mati Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mati Therapeutics.